Search Results - "Thomas, S H L"

Refine Results
  1. 1

    Synthetic cannabinoid receptor agonists: classification and nomenclature by Potts, A. J., Cano, C., Thomas, S. H. L., Hill, S. L.

    Published in Clinical toxicology (Philadelphia, Pa.) (01-02-2020)
    “…Introduction: The emergence of novel psychoactive substances has changed the epidemiology of drugs used recreationally throughout Europe and have posed…”
    Get full text
    Journal Article
  2. 2

    Thioridazine and sudden unexplained death in psychiatric in-patients by Reilly, J. G., Ayis, S. A., Ferrier, I. N., Jones, S. J., Thomas, S. H. L.

    Published in British journal of psychiatry (01-06-2002)
    “…Sudden death has been linked to antipsychotic therapy, but the relative risk associated with specific drugs is unknown. To assess the risk of sudden…”
    Get full text
    Journal Article
  3. 3

    Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service by James, D, Adams, R D, Spears, R, Cooper, G, Lupton, D J, Thompson, J P, Thomas, S H L

    Published in Emergency medicine journal : EMJ (01-08-2011)
    “…To describe the patterns and clinical features of toxicity related to recreational use of mephedrone and other cathinones in the U.K. using data collected by…”
    Get more information
    Journal Article
  4. 4

    Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP) by Thomas, S. H. L., Drici, M. D., Hall, G. C., Crocq, M. A., Everitt, B., Lader, M. H., Jeunne, C. Le, Naber, D., Priori, S., Sturkenboom, M., Thibaut, F., Peuskens, J., Mittoux, A., Tanghøj, P., Toumi, M., Moore, N. D., Mann, R. D.

    Published in Acta psychiatrica Scandinavica (01-11-2010)
    “…Thomas SHL, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, Le Jeunne C, Naber D, Priori S, Sturkenboom M, Thibaut F, Peuskens J, Mittoux A, Tanghøj P, Toumi…”
    Get full text
    Journal Article
  5. 5

    Factors Affecting Drug Concentrations and QT Interval During Thioridazine Therapy by Thanacoody, R H K, Daly, A K, Reilly, J G, Ferrier, I N, Thomas, S H L

    Published in Clinical pharmacology and therapeutics (01-11-2007)
    “…The objective of this study was to investigate factors affecting steady‐state plasma concentrations of thioridazine. A cross‐sectional study of patients…”
    Get full text
    Journal Article
  6. 6

    Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose by Yeates, P. J. A., Thomas, S. H. L.

    Published in British journal of clinical pharmacology (01-01-2000)
    “…Aims Oral activated charcoal is used to treat drug overdose and is effective at reducing drug absorption when administered within 1 h of drug ingestion. There…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Liver unit admission following paracetamol overdose with concentrations below current UK treatment thresholds by Beer, C., Pakravan, N., Hudson, M., Smith, L.T., Simpson, K., Bateman, D.N., Thomas, S.H.L.

    Published in QJM : An International Journal of Medicine (01-02-2007)
    “…Background: It has been suggested that current UK thresholds for treating paracetamol overdose should be reduced, following case reports of patients developing…”
    Get full text
    Journal Article
  9. 9

    Comparison of the Effects of Thioridazine and Mesoridazine on the QT Interval in Healthy Adults After Single Oral Doses by Salih, I S M, Thanacoody, R H K, McKay, G A, Thomas, S H L

    Published in Clinical pharmacology and therapeutics (01-11-2007)
    “…We compared the effects of single doses of thioridazine and mesoridazine on the heart rate‐corrected QT (QTc) interval in healthy adult volunteers. QTc…”
    Get full text
    Journal Article
  10. 10

    Anti‐TNF agents for rheumatoid arthritis by Seymour, H. E., Worsley, A., Smith, J. M., Thomas, S. H. L.

    Published in British journal of clinical pharmacology (01-03-2001)
    “…Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disease with a prevalence of approximately 1% and an annual incidence of 0.04%. Up to 50% of…”
    Get full text
    Journal Article
  11. 11

    Toxicoepidemiology and predictors of death in 2,4-dinitrophenol (DNP) toxicity by Potts, A. J., Bowman, N. J., Seger, D. L., Thomas, S. H. L.

    Published in Clinical toxicology (Philadelphia, Pa.) (03-06-2021)
    “…2,4-Dinitrophenol (DNP) is a highly toxic industrial chemical that is sometimes misused to reduce body fat. Toxicity following ingestion of DNP has recently…”
    Get full text
    Journal Article
  12. 12

    Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England by King, A., Hill, S. L., Pucci, M., Bailey, G., Keating, L., Macfarlane, R., Cantle, F., Hudson, S., Thomas, S. H. L.

    Published in Clinical toxicology (Philadelphia, Pa.) (03-10-2022)
    “…Synthetic cannabinoid receptor agonists (SCRA) are commonly encountered new psychoactive substances. Here we report the recent detection of ADB-BUTINACA in…”
    Get full text
    Journal Article
  13. 13

    Pregnancy outcomes following maternal venlafaxine use: A prospective observational comparative cohort study by Richardson, J.L., Martin, F., Dunstan, H., Greenall, A., Stephens, S., Yates, L.M., Thomas, S.H.L.

    Published in Reproductive toxicology (Elmsford, N.Y.) (01-03-2019)
    “…•No statistically significant differences in the hazard of spontaneous abortion was observed following gestational venlafaxine use compared with either…”
    Get full text
    Journal Article
  14. 14

    Pregnancy outcomes after maternal varenicline use; analysis of surveillance data collected by the European Network of Teratology Information Services by Richardson, J.L., Stephens, S., Yates, L.M., Diav-Citrin, O., Arnon, J., Beghin, D., Kayser, A., Kennedy, D., Cupitt, D., te Winkel, B., Peltonen, M., Kaplan, Y.C., Thomas, S.H.L.

    Published in Reproductive toxicology (Elmsford, N.Y.) (01-01-2017)
    “…•This study provides no signal that varenicline is a major human teratogen.•Varenicline exposed major congenital malformation rate (2.25%).•Rate is considered…”
    Get full text
    Journal Article
  15. 15

    A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England by BATEMAN, D. N, MCELHATTON, P. R, DICKINSON, D, WREN, C, MATTHEWS, J. N. S, O'KEEFFE, M, THOMAS, S. H. L

    Published in European journal of clinical pharmacology (01-11-2004)
    “…Amphetamine exposure is associated with congenital cardiac abnormalities in animals. We previously reported an association between recreational use of…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study by Dunstan, HJ, Mill, AC, Stephens, S, Yates, LM, Thomas, SHL

    “…Objective To conduct enhanced surveillance for signals of teratogenesis following use of the neuraminidase inhibitors zanamivir and oseltamivir in the…”
    Get full text
    Journal Article
  18. 18
  19. 19

    QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients by Reilly, JG, Ayis, SA, Ferrier, IN, Jones, SJ, Thomas, SHL

    Published in The Lancet (British edition) (25-03-2000)
    “…Sudden unexplained death in psychiatric patients may be due to drug-induced arrhythmia, of which lengthening of the rate-corrected QT interval (QTc) on the…”
    Get full text
    Journal Article
  20. 20

    Using poisons information service data to assess the acute harms associated with novel psychoactive substances by Wood, D. M., Hill, S. L., Thomas, S. H. L., Dargan, P. I.

    Published in Drug testing and analysis (01-07-2014)
    “…Novel psychoactive substances (NPS) can cause significant acute toxicity but usually little is known about their toxicity when they enter the recreational drug…”
    Get full text
    Journal Article